Randall Hoover

515 total citations
23 papers, 380 citations indexed

About

Randall Hoover is a scholar working on Pharmacology, Molecular Medicine and Molecular Biology. According to data from OpenAlex, Randall Hoover has authored 23 papers receiving a total of 380 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Pharmacology, 8 papers in Molecular Medicine and 7 papers in Molecular Biology. Recurrent topics in Randall Hoover's work include Antibiotics Pharmacokinetics and Efficacy (12 papers), Antibiotic Resistance in Bacteria (8 papers) and Pneumonia and Respiratory Infections (5 papers). Randall Hoover is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (12 papers), Antibiotic Resistance in Bacteria (8 papers) and Pneumonia and Respiratory Infections (5 papers). Randall Hoover collaborates with scholars based in United States, Italy and United Kingdom. Randall Hoover's co-authors include Sue Cammarata, Susan K. Paulson, Laura Lawrence, Thomas L. Hunt, Eugene Sun, Harry Alcorn, Myron L. Toews, David R. Luke, Jie Zhang and Weizheng Xu and has published in prestigious journals such as Journal of Medicinal Chemistry, Journal of Pharmacology and Experimental Therapeutics and Journal of Antimicrobial Chemotherapy.

In The Last Decade

Randall Hoover

23 papers receiving 369 citations

Peers

Randall Hoover

PHARM

ONCOL

Anita Shah United States

Marie-Béatrice Carlier Belgium

Helen Gu United States

I. Pettinati United Kingdom

Masayasu Sekiguchi Japan

M H Adelman United States

John van Duzer United States

Siddharth Sinha Macao

Yunis Aa United States

Mihailo Banjanac Croatia

Anita Shah United States

Randall Hoover

143 ×0.9

PHARM

28 ×0.2

79 ×0.7

52 ×0.6

ONCOL

58 ×0.8

Citations per year, relative to Randall Hoover Randall Hoover (= 1×) peers Anita Shah

Countries citing papers authored by Randall Hoover

Since Specialization

Citations

This map shows the geographic impact of Randall Hoover's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Randall Hoover with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Randall Hoover more than expected).

Fields of papers citing papers by Randall Hoover

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Randall Hoover. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Randall Hoover. The network helps show where Randall Hoover may publish in the future.

Co-authorship network of co-authors of Randall Hoover

This figure shows the co-authorship network connecting the top 25 collaborators of Randall Hoover. A scholar is included among the top collaborators of Randall Hoover based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Randall Hoover. Randall Hoover is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Arrieta, Antonio, John S. Bradley, Paulo Magalhães, et al.. (2024). Dose rationale for the use of meropenem/vaborbactam combination in paediatric patients with Gram‐negative bacterial infections. British Journal of Clinical Pharmacology. 90(10). 2597–2610. 2 indexed citations

McCurdy, Sandra P., et al.. (2023). Efficacy of delafloxacin against the biothreat pathogenBacillus anthracis. Journal of Antimicrobial Chemotherapy. 78(3). 810–816. 4 indexed citations

Bokesch, Paula M., Antonio Arrieta, John S. Bradley, Randall Hoover, & Sandra P. McCurdy. (2023). 1676. PK, Safety and Tolerability of VABOMERE® (meropenem-vaborbactam) in Infants, Children and Adolescents. Open Forum Infectious Diseases. 10(Supplement_2). 1 indexed citations

Hoover, Randall, et al.. (2022). Kimyrsa, An Oritavancin-Containing Product: Clinical Study and Review of Properties. Open Forum Infectious Diseases. 9(5). ofac090–ofac090. 8 indexed citations

Hoover, Randall, Harry Alcorn, Laura Lawrence, et al.. (2018). Clinical Pharmacokinetics of Sulfobutylether‐β‐Cyclodextrin in Patients With Varying Degrees of Renal Impairment. The Journal of Clinical Pharmacology. 58(6). 814–822. 27 indexed citations

Hoover, Randall, et al.. (2018). Pharmacokinetics of Intravenous Delafloxacin in Patients With End‐Stage Renal Disease. The Journal of Clinical Pharmacology. 58(7). 913–919. 14 indexed citations

Hoover, Randall, et al.. (2017). Delafloxacin Pharmacokinetics in Subjects With Varying Degrees of Renal Function. The Journal of Clinical Pharmacology. 58(4). 514–521. 28 indexed citations

Paulson, Susan K., et al.. (2017). The Pharmacokinetics of the CYP3A Substrate Midazolam After Steady-state Dosing of Delafloxacin. Clinical Therapeutics. 39(6). 1182–1190. 24 indexed citations

Hoover, Randall, et al.. (2017). Human Target Attainment Probabilities for Delafloxacin against Escherichia coli and Pseudomonas aeruginosa. Open Forum Infectious Diseases. 4(suppl_1). S479–S479. 1 indexed citations

10.

Hoover, Randall, Thomas Marbury, Richard A. Preston, et al.. (2016). Clinical Pharmacology of Delafloxacin in Patients With Hepatic Impairment. The Journal of Clinical Pharmacology. 57(3). 328–335. 30 indexed citations

11.

Hoover, Randall, Thomas L. Hunt, Susan K. Paulson, et al.. (2015). Single and Multiple Ascending-dose Studies of Oral Delafloxacin: Effects of Food, Sex, and Age. Clinical Therapeutics. 38(1). 39–52. 44 indexed citations

12.

Hoover, Randall, Thomas L. Hunt, Susan K. Paulson, et al.. (2015). Safety, Tolerability, and Pharmacokinetic Properties of Intravenous Delafloxacin After Single and Multiple Doses in Healthy Volunteers. Clinical Therapeutics. 38(1). 53–65. 45 indexed citations

13.

Hoover, Randall, et al.. (2015). A Phase 1, Open-Label, Evaluation of the Single-Dose Pharmacokinetics of Delafloxacin (DLX) in Subjects With and Without Hepatic Impairment. Open Forum Infectious Diseases. 2(suppl_1). 1 indexed citations

14.

Rais, Rana, Randall Hoover, Krystyna M. Wozniak, et al.. (2012). Reversible Disulfide Formation of the Glutamate Carboxypeptidase II Inhibitor E2072 Results in Prolonged Systemic Exposures In Vivo. Drug Metabolism and Disposition. 40(12). 2315–2323. 7 indexed citations

15.

Araki, Koji, Jie Zhang, Weizheng Xu, et al.. (2009). Head and neck cancer radiosensitization by the novel poly(ADP‐ribose) polymerase inhibitor GPI‐15427. Head & Neck. 32(3). 381–391. 55 indexed citations

16.

Tentori, Lucio, Carlo Leonetti, Marco Scarsella, et al.. (2005). Brain distribution and efficacy as chemosensitizer of an oral formulation of PARP-1 inhibitor GPI 15427 in experimental models of CNS tumors. International Journal of Oncology. 26(2). 415–22. 33 indexed citations

17.

Tentori, Lucio, Carlo Leonetti, Marco Scarsella, et al.. (2004). Oral administration of the PARP-1 inhibitor GPI 15427 increases the anti-tumor activity of temozolomide against melanoma growing at the CNS site. Cineca Institutional Research Information System (Tor Vergata University). 45. 2007. 1 indexed citations

18.

Jain, Jugnu, Randall Hoover, Pamella J. Ford, et al.. (2004). 488 VX-944: an inosine monophosphate dehydrogenase inhibitor with unique anti-cancer activity. European Journal of Cancer Supplements. 2(8). 149–149. 3 indexed citations

19.

Hoover, Randall & Myron L. Toews. (1990). Activation of protein kinase C inhibits internalization and downregulation of muscarinic receptors in 1321N1 human astrocytoma cells.. Journal of Pharmacology and Experimental Therapeutics. 253(1). 185–191. 15 indexed citations

20.

Hoover, Randall & M L Toews. (1989). Evidence for an agonist-induced, ATP-dependent change in muscarinic receptors of intact 1321N1 cells.. Journal of Pharmacology and Experimental Therapeutics. 251(1). 63–70. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact